1
|
Singh V, Shirbhate E, Kore R, Mishra A, Johariya V, Veerasamy R, Tiwari AK, Rajak H. Dietary Plant Metabolites Induced Epigenetic Modification as a Novel Strategy for the Management of Prostate Cancer. Mini Rev Med Chem 2024; 24:1409-1426. [PMID: 38385496 DOI: 10.2174/0113895575283895240207065454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2023] [Revised: 01/10/2024] [Accepted: 01/19/2024] [Indexed: 02/23/2024]
Abstract
Prostate cancer is a widespread malignancy among men, with a substantial global impact on morbidity and mortality. Despite advances in conventional therapies, the need for innovative and less toxic treatments remains a priority. Emerging evidence suggests that dietary plant metabolites possess epigenetic-modifying properties, making them attractive candidates for prostate cancer treatment. The present work reviews the epigenetic effects of dietary plant metabolites in the context of prostate cancer therapy. We first outline the key epigenetic mechanisms involved in prostate cancer pathogenesis, including histone modifications, DNA methylation, and miRNA or Long Noncoding RNA (lncRNA) dysregulation. Next, we delve into the vast array of dietary plant metabolites that have demonstrated promising anti-cancer effects through epigenetic regulation. Resveratrol, minerals, isothiocyanates, curcumin, tea polyphenols, soy isoflavones and phytoestrogens, garlic compounds, anthocyanins, lycopene, and indoles are among the most extensively studied compounds. These plant-derived bioactive compounds have been shown to influence DNA methylation patterns, histone modifications, and microRNA expression, thereby altering the gene expression allied with prostate cancer progression, cell proliferation, and apoptosis. We also explore preclinical and clinical studies investigating the efficacy of dietary plant metabolites as standalone treatments or in combination with traditional treatments for people with prostate cancer. The present work highlights the potential of dietary plant metabolites as epigenetic modulators to treat prostate cancer. Continued research in this field may pave the way for personalized and precision medicine approaches, moving us closer to the goal of improved prostate cancer management.
Collapse
Affiliation(s)
- Vaibhav Singh
- Department of Pharmacy, Guru Ghasidash Vishwavidyalaya University, Bilaspur-495 009, (C.G.), India
| | - Ekta Shirbhate
- Department of Pharmacy, Guru Ghasidash Vishwavidyalaya University, Bilaspur-495 009, (C.G.), India
| | - Rakesh Kore
- Department of Pharmacy, Guru Ghasidash Vishwavidyalaya University, Bilaspur-495 009, (C.G.), India
| | - Aditya Mishra
- Department of Pharmacy, Guru Ghasidash Vishwavidyalaya University, Bilaspur-495 009, (C.G.), India
| | - Varsha Johariya
- Department of Pharmacy, Guru Ghasidash Vishwavidyalaya University, Bilaspur-495 009, (C.G.), India
| | - Ravichandran Veerasamy
- Departement of Pharmaceutical chemistry, Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia
| | - Amit K Tiwari
- UAMS College of Pharmacy, College of Pharmacy and Pharmaceutical Sciences, UAMS - University of Arkansas for Medical Sciences, Arkansas, (AR) USA
| | - Harish Rajak
- Department of Pharmacy, Guru Ghasidash Vishwavidyalaya University, Bilaspur-495 009, (C.G.), India
| |
Collapse
|
2
|
Adjakly M, Ngollo M, Dagdemir A, Judes G, Pajon A, Karsli-Ceppioglu S, Penault-Llorca F, Boiteux JP, Bignon YJ, Guy L, Bernard-Gallon D. Prostate cancer: The main risk and protective factors-Epigenetic modifications. ANNALES D'ENDOCRINOLOGIE 2015; 76:25-41. [PMID: 25592466 DOI: 10.1016/j.ando.2014.09.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Revised: 06/18/2014] [Accepted: 09/09/2014] [Indexed: 01/14/2023]
Abstract
With 13 million new cases worldwide every year, prostate cancer is as a very real public health concern. Prostate cancer is common in over-50s men and the sixth-leading cause of cancer-related death in men worldwide. Like all cancers, prostate cancer is multifactorial - there are non-modifiable risk factors like heredity, ethnicity and geographic location, but also modifiable risk factors such as diet. Diet-cancer linkages have risen to prominence in the last few years, with accruing epidemiological data pointing to between-population incidence differentials in numerous cancers. Indeed, there are correlations between fat-rich diet and risk of hormone-dependent cancers like prostate cancer and breast cancer. Diet is a risk factor for prostate cancer, but certain micronutrients in specific diets are considered protective factors against prostate cancer. Examples include tomato lycopene, green tea epigallocatechin gallate, and soy phytoestrogens. These micronutrients are thought to exert cancer-protective effects via anti-oxidant pathways and inhibition of cell proliferation. Here, we focus in on the effects of phytoestrogens, and chiefly genistein and daidzein, which are the best-researched to date. Soy phytoestrogens are nonsteroid molecules whose structural similarity lends them the ability to mimic the effects of 17ß-estradiol. On top of anti-oxidant effects, there is evidence that soy phytoestrogens can modulate the epigenetic modifications found in prostate cancer. We also studied the impact of phytoestrogens on epigenetic modifications in prostate cancer, with special focus on DNA methylation, miRNA-mediated regulation and histone modifications.
Collapse
Affiliation(s)
- Mawussi Adjakly
- Département d'oncogénétique, CBRV, centre Jean-Perrin, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand, France; ERTICA, EA4677, université d'Auvergne, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France
| | - Marjolaine Ngollo
- Département d'oncogénétique, CBRV, centre Jean-Perrin, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand, France; ERTICA, EA4677, université d'Auvergne, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France
| | - Aslihan Dagdemir
- Département d'oncogénétique, CBRV, centre Jean-Perrin, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand, France; ERTICA, EA4677, université d'Auvergne, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France
| | - Gaëlle Judes
- Département d'oncogénétique, CBRV, centre Jean-Perrin, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand, France; ERTICA, EA4677, université d'Auvergne, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France
| | - Amaury Pajon
- Département d'oncogénétique, CBRV, centre Jean-Perrin, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand, France; ERTICA, EA4677, université d'Auvergne, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France
| | - Seher Karsli-Ceppioglu
- Département d'oncogénétique, CBRV, centre Jean-Perrin, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand, France; ERTICA, EA4677, université d'Auvergne, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France; Département de toxicologie, faculté de pharmacie, université de Marmara, Istanbul, Turkey
| | - Frédérique Penault-Llorca
- ERTICA, EA4677, université d'Auvergne, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France; Laboratoire de pathologie médicale, centre Jean-Perrin, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - Jean-Paul Boiteux
- Département d'urologie, CHU Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - Yves-Jean Bignon
- Département d'oncogénétique, CBRV, centre Jean-Perrin, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand, France; ERTICA, EA4677, université d'Auvergne, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France.
| | - Laurent Guy
- ERTICA, EA4677, université d'Auvergne, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France; Département d'urologie, CHU Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - Dominique Bernard-Gallon
- Département d'oncogénétique, CBRV, centre Jean-Perrin, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand, France; ERTICA, EA4677, université d'Auvergne, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France
| |
Collapse
|